Acute myocardial infarction in an elderly patient treated for lung cancer

• Authors: Piotr Plecka
• Languages of publication: EN

Abstracts

EN

There is a growing number of elderly patients, so it is necessary to create new standards of oncologic care for such individuals in order to provide them with the best possible treatment. An elderly woman was treated for locally advanced small-cell lung cancer. Due to the suspicion of coronary disease, arterial hypertension and age, anti-cancer treatment with carboplatin and etoposide was recommended. When carboplatin infusion came to a stop, signs of myocardial infarction in ECG as well as elevated levels of troponin I were reported. Originally, non-invasive treatment was introduced, but several days later three DES stents were placed in coronary arteries. An attempt was made to treat the patient with cisplatin and etoposide, after which respiratory failure, tumor lysis syndrome and pancytopenia occurred. That is why chemotherapy was discontinued at the time. The patient’s tumor area and brain was irradiated. 16 months later, she is still alive without signs of disease progression. New oncologic standards should be elaborated in order to ensure appropriate treatment for elderly patients.

Keywords

EN

carboplatin cardiotoxicity; elderly patients; myocardial infarction

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2018
• Volume: 8
• Issue: 3
• Pages: 76-79

Contributors

author

Piotr Plecka

• Department of Medicine and Health Sciences, University of Zielona Góra; Oncology Clinic in Dębno Lubuskie

References

• 1. Wojciechowska U, Didkowska J. Krajowy Rejestr Nowotworów, Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie [online: onkologia.org. pl/raporty/ accessed 17.07.2018 r.].
• 2. Rechel B, Grundy E, Robine JM et al. Ageing in the European Union. Lancet 2013; 381: 1312-1322.
• 3. Ludbrook JJ, Truong PT, MacNeil MV et al. Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? A community-based population analysis. Int J Radiat Oncol Biol Phys 2003; 55: 1321-1330.
• 4. Kowalski DM, Szmit S. Ocena ryzyka powikłań sercowo-naczyniowych u chorych na raka płuca otrzymujących leki cytotoksyczne i ukierunkowane molekularnie. In: Krzakowski M, Opolski G, Szmit S. (ed). Postępowanie w powikłaniach sercowo-naczyniowych w raku płuca. Medical Education, Warszawa 2012: 77-85.
• 5. Meriggi F, Zaniboni A. Non-small cell lung cancer in the elderly. Crit Rev Oncol Hematol 2006; 57: 183-190.
• 6. Hurria A, Togawa K, Mohile SG et al. Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study. J Clin Oncol 2011; 29(25): 3457-3465. DOI: 10. 1200/JCO.2011.34.7625.
• 7. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748.
• 8. Sculier JP, Botta I, Bucalau AM et al. Medical anticancer treatment of lung cancer associated with comorbidities: a review. Lung Cancer 2015; pii: S0169-5002(15)00065-3.
• 9. Berliner S, Rahima R, Sidi Y et al. Acute coronary events following cisplatin-based chemotherapy. Cancer Invest 1990; 8(6): 583-586.
• 10. Kim ES, Baran AM, Mondo EL et al. Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer. PLoS ONE 2017; 12(12): e0189410 [online: https://doi.org/10.1371/journal.pone.0189410].

• Document Type: article